The biopharma industry stands at a transformative juncture as it reflects on the achievements of the past year and anticipates the evolving client requirements that will shape 2025 and beyond. Key insights from Subodh Deshmukh, CEO of Aragen Bioscience, highlight the crucial areas of focus for
Thermo Fisher Scientific is taking bold steps toward revolutionizing drug development through its innovative Accelerator Drug Development program. This strategy aims to streamline the complex process from preclinical stages to commercialization by integrating its contract research organization
Antibody development is integral to pushing the boundaries of research, diagnostics, and therapeutics. Characterized by their high specificity and affinity, antibodies are critical for detecting and neutralizing biological targets, leading to significant breakthroughs across various scientific
The US Food and Drug Administration (FDA) raised serious concerns about Sanofi's manufacturing facility in Framingham, Massachusetts, by issuing a Warning Letter for significant deviations from current Good Manufacturing Practice (cGMP) standards for drug substance production. This alarming
In an optimistic outlook at the 43rd JPM Conference in San Francisco, Thermo Fisher CEO Marc Casper underscored the firm's strategic adaptations and growth initiatives tailored to meet surging demand for GLP-1 diabetes and weight loss products. Thermo Fisher Scientific's extensive investment in its
The contract development and manufacturing organization (CDMO) industry has seen significant advancements and partnerships as of January 2025. With a focus on large molecules and advanced therapies, this article delves into the latest developments, highlighting key trends, common themes, and
